612 related articles for article (PubMed ID: 29414548)
1. Efficacy and tolerability of perampanel and levetiracetam as first add-on therapy in patients with epilepsy: A retrospective single center study.
Liguori C; Izzi F; Manfredi N; D'Elia A; Mari L; Mercuri NB; Fabio P
Epilepsy Behav; 2018 Mar; 80():173-176. PubMed ID: 29414548
[TBL] [Abstract][Full Text] [Related]
2. Preliminary evidence about irritability in patients with epilepsy treated by perampanel as first add-on therapy compared to levetiracetam and valproic acid.
Liguori C; Turner K; Izzi F; Assogna M; Canevini MP; Mercuri NB; Placidi F
CNS Neurosci Ther; 2019 May; 25(5):632-637. PubMed ID: 30675751
[TBL] [Abstract][Full Text] [Related]
3. Psychiatric and behavioral concerns of perampanel with concomitant levetiracetam in children with epilepsy.
Kim JS; Kim WS; Sung WY; Woo H
Epilepsy Behav; 2024 May; 154():109740. PubMed ID: 38547767
[TBL] [Abstract][Full Text] [Related]
4. Usefulness of perampanel with concomitant levetiracetam for patients with drug-resistant epilepsy.
Kanemura H; Sano F; Aihara M
Eur J Paediatr Neurol; 2019 Jan; 23(1):197-203. PubMed ID: 30424990
[TBL] [Abstract][Full Text] [Related]
5. One-year clinical experience of perampanel in Spain: a multicentre study of efficacy and tolerability.
Garamendi-Ruiz I; García-García ME; Bertol-Alegre V; Mauri-Llerda JÁ; García-Morales I; Garayoa-Irigoyen V; Agúndez-Sarasola M; De Toledo-Heras M; García-Morales V; García-Gomara MJ; Arcos-Sánchez C; Gago-Veiga A; Escalza-Cortina I; Rueda-Mena E; Muñoz-Fargas E; Santos-Lasaosa S; Oliván-Usieto JA; Julián LD; Gómez-Esteban JC; Marinas-Alejo A
Epileptic Disord; 2016 Jun; 18(2):173-80. PubMed ID: 27238234
[TBL] [Abstract][Full Text] [Related]
6. Effectiveness and safety of perampanel as early add-on treatment in patients with epilepsy and focal seizures in the routine clinical practice: Spain prospective study (PERADON).
Abril Jaramillo J; Estévez María JC; Girón Úbeda JM; Vega López Ó; Calzado Rivas ME; Pérez Díaz H; García Martín G; Vila Herrero E; Chamorro-Muñoz M; Vázquez F; De la Fuente C; Redondo L; Peláez N; Santágueda P; Rodríguez Uranga JJ
Epilepsy Behav; 2020 Jan; 102():106655. PubMed ID: 31812902
[TBL] [Abstract][Full Text] [Related]
7. Experience of Low Dose Perampanel to Add-on in Glioma Patients with Levetiracetam-uncontrollable Epilepsy.
Chonan M; Saito R; Kanamori M; Osawa SI; Watanabe M; Suzuki H; Nakasato N; Tominaga T
Neurol Med Chir (Tokyo); 2020 Jan; 60(1):37-44. PubMed ID: 31748440
[TBL] [Abstract][Full Text] [Related]
8. Eslicarbazepine acetate as a replacement for levetiracetam in people with epilepsy developing behavioral adverse events.
Jalihal V; Shankar R; Henley W; Parrett M; Tittensor P; McLean BN; Ahmed A; Sander JW
Epilepsy Behav; 2018 Mar; 80():365-369. PubMed ID: 29415871
[TBL] [Abstract][Full Text] [Related]
9. Adjunctive brivaracetam in focal and generalized epilepsies: A single-center open-label prospective study in patients with psychiatric comorbidities and intellectual disability.
Foo EC; Geldard J; Peacey C; Wright E; Eltayeb K; Maguire M
Epilepsy Behav; 2019 Oct; 99():106505. PubMed ID: 31493736
[TBL] [Abstract][Full Text] [Related]
10. Adjunctive perampanel in refractory epilepsy: Experience at tertiary epilepsy care center in Tours.
Maurousset A; Limousin N; Praline J; Biberon J; Corcia P; De Toffol B
Epilepsy Behav; 2016 Aug; 61():237-241. PubMed ID: 27393930
[TBL] [Abstract][Full Text] [Related]
11. Final safety, tolerability, and seizure outcomes in patients with focal epilepsy treated with adjunctive perampanel for up to 4 years in an open-label extension of phase III randomized trials: Study 307.
Krauss GL; Perucca E; Kwan P; Ben-Menachem E; Wang XF; Shih JJ; Patten A; Yang H; Williams B; Laurenza A
Epilepsia; 2018 Apr; 59(4):866-876. PubMed ID: 29574701
[TBL] [Abstract][Full Text] [Related]
12. Safety and efficacy of perampanel in children and adults with various epilepsy syndromes: A single-center postmarketing study.
Singh K; Shah YD; Luciano D; Friedman D; Devinsky O; Kothare SV
Epilepsy Behav; 2016 Aug; 61():41-45. PubMed ID: 27300147
[TBL] [Abstract][Full Text] [Related]
13. Improved irritability, mood, and quality of life following introduction of perampanel as late adjunctive treatment for epilepsy.
Moraes JS; Hepworth G; Ignatiadis S; Dharan A; Carne R; Seneviratne U; Cook MJ; D'Souza WJ
Epilepsy Behav; 2020 Mar; 104(Pt A):106883. PubMed ID: 32045874
[TBL] [Abstract][Full Text] [Related]
14. A systematic review and indirect treatment comparison of perampanel versus brivaracetam as adjunctive therapy in patients with focal-onset seizures with or without secondary generalization.
Trinka E; Tsong W; Toupin S; Patten A; Wilson K; Isojarvi J; James D
Epilepsy Res; 2020 Oct; 166():106403. PubMed ID: 32673969
[TBL] [Abstract][Full Text] [Related]
15. A randomized, open-label, multicenter comparative trial of levetiracetam and topiramate as adjunctive treatment for patients with focal epilepsy in Korea.
Lee SK; Lee SA; Kim DW; Loesch C; Pelgrims B; Osakabe T; Lee B;
Epilepsy Behav; 2019 Aug; 97():67-74. PubMed ID: 31195326
[TBL] [Abstract][Full Text] [Related]
16. Favorable adverse effect profile of brivaracetam vs levetiracetam in a preclinical model.
Sanon NT; Gagné J; Wolf DC; Aboulamer S; Bosoi CM; Simard A; Messiet E; Desgent S; Carmant L
Epilepsy Behav; 2018 Feb; 79():117-125. PubMed ID: 29287214
[TBL] [Abstract][Full Text] [Related]
17. Long-term efficacy and safety of lacosamide and levetiracetam monotherapy in elderly patients with focal epilepsy: A retrospective study.
Del Bianco C; Placidi F; Liguori C; Mari L; Ulivi M; Ornello R; Pisani A; Mercuri NB; Izzi F
Epilepsy Behav; 2019 May; 94():178-182. PubMed ID: 30959275
[TBL] [Abstract][Full Text] [Related]
18. Quality of life, mood and seizure control in patients with brain tumor related epilepsy treated with lacosamide as add-on therapy: A prospective explorative study with a historical control group.
Maschio M; Zarabla A; Maialetti A; Fabi A; Vidiri A; Villani V; Giannarelli D
Epilepsy Behav; 2017 Aug; 73():83-89. PubMed ID: 28623754
[TBL] [Abstract][Full Text] [Related]
19. [Perampanel in pharmacotherapy of focal epilepsy: the efficacy and tolerability in routine clinical practice].
Zhidkova IA; Karlov VA; Vlasov PN
Zh Nevrol Psikhiatr Im S S Korsakova; 2016; 116(9. Vyp. 2):82-88. PubMed ID: 28005052
[TBL] [Abstract][Full Text] [Related]
20. Comparison of the effectiveness and tolerability of perampanel and brivaracetam: a real-world, observational, retrospective study.
Liguori C; Manfredi N; Renna R; Izzi F; Pagliuca M; Pagliuca F; Mercuri NB; Fabio P
Epileptic Disord; 2020 Jun; 22(3):309-316. PubMed ID: 32540833
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
